BRIEF published on 04/17/2025 at 07:05, 1 year 2 months ago Evotec SE présente sa nouvelle stratégie et ses prévisions pour 2025 après de solides performances au quatrième trimestre 2024 Evotec SE Partenariats Stratégie 2025 Résultats Du Quatrième Trimestre 2024 Orientation De Croissance
BRIEF published on 04/17/2025 at 07:05, 1 year 2 months ago Evotec SE Outlines New Strategy with 2025 Guidance Following Strong Q4 2024 Performance Evotec SE 2025 Strategy Partnerships Growth Guidance Q4 2024 Results
PRESS RELEASE published on 04/17/2025 at 07:00, 1 year 2 months ago Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results Evotec SE unveils new strategy and provides 2025 guidance with strong Q4 2024 results, focusing on drug discovery and sustainable growth Evotec SE Sustainable Growth New Strategy 2025 Guidance Q4 2024 Results
BRIEF published on 04/10/2025 at 11:30, 1 year 2 months ago Evotec SE to Release 2024 Financial Results on April 17, 2025 Financial Results Conference Call Evotec SE Webcast Therapeutics
BRIEF published on 04/10/2025 at 11:30, 1 year 2 months ago Evotec SE publiera ses résultats financiers 2024 le 17 avril 2025 Résultats Financiers Evotec SE Webcast Conférence Téléphonique Thérapeutique
PRESS RELEASE published on 04/10/2025 at 11:25, 1 year 2 months ago Evotec SE to announce results for financial year 2024 on 17 April 2025 Evotec SE to announce financial results for 2024 on April 17, 2025, followed by a conference call discussing strategic review and updates. Webcast and dial-in details provided Financial Results Conference Call Evotec SE Webcast Strategic Review
BRIEF published on 03/04/2025 at 07:35, 1 year 3 months ago Evotec's Neuroscience Collaboration with Bristol Myers Squibb Progresses Strategic Partnership Evotec SE Innovative Treatments Bristol Myers Squibb Neurodegeneration
BRIEF published on 03/04/2025 at 07:35, 1 year 3 months ago La collaboration entre Evotec et Bristol Myers Squibb dans le domaine des neurosciences progresse Evotec SE Partenariat Stratégique Bristol Myers Squibb Neurodégénérescence Des Traitements Innovants
PRESS RELEASE published on 03/04/2025 at 07:30, 1 year 3 months ago Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb Evotec SE announces key progress in neuroscience collaboration with Bristol Myers Squibb, receiving a $20 million payment for neurodegeneration research Evotec SE Bristol Myers Squibb Neuroscience Collaboration Neurodegeneration Research Progress
BRIEF published on 02/26/2025 at 07:35, 1 year 4 months ago Evotec annonce une transition exécutive au poste de directeur financier Croissance Durable Changement De Direction Evotec Leadership Financier Paul Hitchin
Published on 06/27/2026 at 16:50, 6 hours 29 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 21 hours 39 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 23 hours 19 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 23 hours 14 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 23 hours 15 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 23 hours 43 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 23 hours 43 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 23 hours 52 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
